Author

K. Bhukhai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:protein sequence· 1

Frequent Co-Authors

A. Thitithanyanont· 2 shared C. Seephetdee· 2 shared N. Buasri· 2 shared N. Phueakphud· 2 shared P. Wongtrakoongate· 2 shared S. Hongeng· 2 shared S. Manopwisedjaroen· 2 shared C. Pakiranay· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Thitithanyanont

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Broad neutralization of SARS-CoV-2 variants by circular mRNA producing VFLIP-X spike in mice

C. Seephetdee, K. Bhukhai, N. Buasri, P. Leelukkanaveera, P. Lerdwattanasombat, S. Manopwisedjaroen, N. Phueakphud, S. Kuhaudomlarp, E. Olmedillas, E. Ollmann Saphire, A. Thitithanyanont, S. Hongeng, P. Wongtrakoongate

This study shows that a circular mRNA vaccine encoding VFLIP-X spike protein induces broad neutralizing antibodies against SARS-CoV-2 variants in mice.

bioRxiv · Mar 17, 2022 · PreprintImmunology

Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2

C. Seephetdee, N. Buasri, K. Bhukhai, K. Srisanga, S. Manopwisedjaroen, S. Lertjintanakit, N. Phueakphud, C. Pakiranay, N. Kangwanrangsan, S. Srichatrapimuk, S. Sungkanuparph, S. Kirdlarp, S. Chutipongtanate, A. Thitithanyanont, S. Hongeng, P. Wongtrakoongate

This study shows that mice vaccinated with HexaPro spike protein produce high-titer neutralizing antibodies against SARS-CoV-2 for up to 56 days.

bioRxiv · Feb 27, 2021Immunology